Meeting
2023 ASCO Annual Meeting
BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.
Authors
Guilherme Fleury Perini
Hospital Paulistano and Instituto Américas, São Paulo, Brazil
Guilherme Fleury Perini , Carolyn Owen , Muhit Ozcan , Wojciech Jurczak , Eva González Barca , Tomasz Wrobel , David Lavie , Arvind Chaudhry , Paolo Ghia , Yan Xu , David Boardman , Jing Yang , Ohad Benjamini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT04728893
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7593)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7593
Abstract #
TPS7593
Poster Bd #
137a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
First Author: Pier Luigi Zinzani
Poster
2022 ASCO Annual Meeting
Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
First Author: Patrick Y. Wen
Poster
2018 ASCO Annual Meeting
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
First Author: Paul A. Hamlin
